KYNB
Income statement / Annual
Last year (2024), FibroGen, Inc.'s total revenue was $29.62 M,
a decrease of 36.71% from the previous year.
In 2024, FibroGen, Inc.'s net income was -$47.58 M.
See FibroGen, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$29.62 M |
$46.80 M |
$140.73 M |
$235.31 M |
$176.32 M |
$256.58 M |
$212.96 M |
$131.00 M |
$179.58 M |
$180.83 M |
| Cost of Revenue |
$15.56 M
|
$10.58 M
|
$20.28 M
|
$27.68 M
|
$30.92 M
|
$22.60 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$14.06 M
|
$36.22 M
|
$120.45 M
|
$207.63 M
|
$145.40 M
|
$233.98 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.47
|
0.77
|
0.86
|
0.88
|
0.82
|
0.91
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$95.69 M
|
$263.16 M
|
$296.79 M
|
$387.04 M
|
$252.92 M
|
$209.27 M
|
$235.84 M
|
$196.52 M
|
$187.21 M
|
$214.09 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$49.33 M
|
$83.17 M
|
$124.69 M
|
$109.12 M
|
$84.36 M
|
$114.03 M
|
$57.25 M
|
$45.66 M
|
$39.99 M
|
$38.69 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$145.02 M
|
$346.34 M
|
$421.48 M
|
$496.16 M
|
$337.28 M
|
$323.29 M
|
$293.09 M
|
$242.18 M
|
$227.19 M
|
$252.77 M
|
| Cost And Expenses |
$160.58 M
|
$356.92 M
|
$441.76 M
|
$523.84 M
|
$368.20 M
|
$345.89 M
|
$299.65 M
|
$248.28 M
|
$233.23 M
|
$258.45 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$8.25 M
|
$8.10 M
|
$1.44 M
|
$1.08 M
|
$2.40 M
|
$2.88 M
|
$10.99 M
|
$9.71 M
|
$10.73 M
|
$11.03 M
|
| Depreciation & Amortization |
$2.69 M
|
$9.93 M
|
$10.60 M
|
$14.81 M
|
$22.05 M
|
$21.45 M
|
$6.56 M
|
$6.10 M
|
$6.04 M
|
$5.68 M
|
| EBITDA |
-$142.43 M |
-$305.20 M |
-$282.83 M |
-$274.80 M |
-$164.28 M |
-$52.31 M |
-$68.56 M |
-$104.75 M |
-$44.99 M |
-$68.83 M |
| EBITDA Ratio |
-4.81
|
-6.52
|
-2.01
|
-1.17
|
-0.93
|
-0.2
|
-0.32
|
-0.8
|
-0.25
|
-0.38
|
| Operating Income Ratio |
-4.42
|
-6.63
|
-2.14
|
-1.23
|
-1.09
|
-0.35
|
-0.41
|
-0.9
|
-0.3
|
-0.43
|
| Total Other Income/Expenses Net |
-$22.41 M
|
-$13.11 M
|
$7.73 M
|
-$1.15 M
|
$2.95 M
|
$12.67 M
|
$577.00 K
|
-$3.27 M
|
-$8.10 M
|
-$7.91 M
|
| Income Before Tax |
-$153.37 M
|
-$323.22 M
|
-$293.30 M
|
-$289.68 M
|
-$188.93 M
|
-$76.64 M
|
-$86.12 M
|
-$120.55 M
|
-$61.75 M
|
-$85.54 M
|
| Income Before Tax Ratio |
-5.18
|
-6.91
|
-2.08
|
-1.23
|
-1.07
|
-0.3
|
-0.4
|
-0.92
|
-0.34
|
-0.47
|
| Income Tax Expense |
-$269.00 K
|
-$252.00 K
|
$358.00 K
|
$347.00 K
|
$360.00 K
|
$328.00 K
|
$304.00 K
|
$321.00 K
|
-$71.00 K
|
$242.00 K
|
| Net Income |
-$47.58 M
|
-$284.23 M
|
-$293.65 M
|
-$290.02 M
|
-$189.29 M
|
-$76.97 M
|
-$86.42 M
|
-$120.88 M
|
-$61.68 M
|
-$85.78 M
|
| Net Income Ratio |
-1.61
|
-6.07
|
-2.09
|
-1.23
|
-1.07
|
-0.3
|
-0.41
|
-0.92
|
-0.34
|
-0.47
|
| EPS |
-11.89 |
-73.03 |
-78.45 |
-78.51 |
-52.67 |
-22.21 |
-25.7 |
-41.4 |
-24.5 |
-35.5 |
| EPS Diluted |
-11.89 |
-73.03 |
-78.45 |
-78.51 |
-52.67 |
-22.21 |
-25.7 |
-41.4 |
-24.5 |
-35.5 |
| Weighted Average Shares Out |
$4.00 M
|
$3.89 M
|
$3.74 M
|
$3.69 M
|
$3.59 M
|
$3.47 M
|
$3.36 M
|
$2.92 M
|
$2.51 M
|
$2.41 M
|
| Weighted Average Shares Out Diluted |
$4.00 M
|
$3.89 M
|
$3.74 M
|
$3.69 M
|
$3.59 M
|
$3.47 M
|
$3.36 M
|
$2.92 M
|
$2.51 M
|
$2.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
